Icure Pharmaceutical Incorporation

A175250

KR7175250000

Personal Products

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-05-12 EDT			5-day change	1st Jan Change
1,818 ^KRW	-1.20%		-1.62%	-13.01%

03-20	Icure Pharmaceutical Incorporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Icure Pharmaceutical Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Icure Pharmaceutical Incorporation announced that it expects to receive KRW 50 billion in funding

January 28, 2021

Icure Pharmaceutical Incorporation (KOSDAQ:A175250) announced a private placement of round 4th unregistered coupon nonguaranteed private convertible bond for the gross proceeds of KRW 50,000,000,000 on January 29, 2021. The transaction has been approved by board of directors.

Latest news about Icure Pharmaceutical Incorporation

Icure Pharmaceutical Incorporation Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
Icure Pharmaceutical Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Icure Pharmaceutical Incorporation(KOSDAQ:A175250) dropped from S&P Global BMI Index	23-09-18	CI
Icure Pharmaceutical Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Icure Pharmaceutical Incorporation announced that it has received KRW 5 billion in funding	23-07-10	CI
Icure Pharmaceutical Incorporation announced that it expects to receive KRW 5 billion in funding	23-07-06	CI
Icure Pharmaceutical Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Icure Pharmaceutical Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-11	CI
Icure Pharmaceutical to Raise $57 Million from Share Sale	22-09-19	MT
Icure Pharmaceutical Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
Icure Pharmaceutical Incorporation Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-23	CI
Tranche Update on Icure Pharmaceutical Incorporation's Equity Buyback Plan announced on February 25, 2022.	22-03-11	CI
Icure Pharmaceutical Incorporation's Equity Buyback announced on February 25, 2022, has closed with 40,323 shares, representing 0.23% for KRW 547.51 million.	22-03-06	CI
Icure Pharmaceutical Incorporation announces an Equity Buyback for 40,323 shares.	22-02-25	CI
Icure Pharmaceutical Incorporation authorizes a Buyback Plan.	22-02-24	CI
Icure Acquires Drug Product Approval for Donepezil Patch for Treating Dementia of the Alzheimer Type in Korea	21-11-16	CI
Icure Pharmaceutical Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-12	CI
Cosnine Co., Ltd. announced that it has received KRW 6.0116 billion in funding from Icure Pharmaceutical Incorporation	21-02-24	CI
Cosnine Co., Ltd. announced that it expects to receive KRW 6.0116 billion in funding from Icure Pharmaceutical Incorporation	21-02-09	CI
Icure Pharmaceutical Incorporation announced that it has received KRW 50 billion in funding	21-02-01	CI
Icure Pharmaceutical Incorporation announced that it expects to receive KRW 50 billion in funding	21-01-28	CI
Cosnine Co., Ltd. announced that it has received KRW 4 billion in funding from Icure Pharmaceutical Incorporation and another investor	20-12-02	CI
Cosnine Co., Ltd. announced that it expects to receive KRW 4 billion in funding from Icure Pharmaceutical Incorporation and another investor	20-11-02	CI
Prostemics Co., Ltd. agreed to acquire OTKCNT Co., Ltd. from Icure Pharmaceutical Incorporation and Gang, Seok-Ho for KRW 17 billion.	20-08-05	CI
Icure Pharm. Inc. cancelled the acquisition of 90% stake in OTKCNT Co., Ltd. from an unknown seller.	20-04-04	CI

Chart Icure Pharmaceutical Incorporation

Duration

Period

Chart Icure Pharmaceutical Incorporation

More charts

Company Profile

Icure Pharmaceutical Incorporation is a Korea-based company mainly engaged in the production and sale of cosmetics. Along with subsidiaries, the Company operates its business through two segments. The Cosmetic segment is involved in the manufacturing and sale of cosmetics including basic cosmetics, mask packs, and patches. In addition, it is also engaged in the production and sale of body, hair care products and fragrances. The cosmetics are sold under the names of Botalinum, Mediheal N.M.F, Meditime, among others. The Pharmaceutical segment is engaged in the manufacturing and sale of over the counter (OTC) drugs, ethical the counter (ETC) drugs, as well as quasi drugs. The OTC drugs include anti-inflammatory analgesics and dementia treatments. The Company distributes its products within the domestic market and to overseas markets.

Sector

Personal Products

Calendar

2024-08-12 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Cosmetics & Perfumes

	1st Jan change	Capi.
ICURE PHARMACEUTICAL INCORPORATION	-13.01%	50.21M
KAO CORPORATION	+18.31%	20.69B
GALDERMA GROUP AG	0.00%	18.4B
SHISEIDO COMPANY, LIMITED	+9.50%	11.56B
COTY INC.	-10.06%	9.69B
AMOREPACIFIC CORPORATION	+16.41%	7.66B
PROYA COSMETICS CO.,LTD.	+12.57%	6.19B
NATURA &CO HOLDING S.A.	+3.02%	4.62B
INTER PARFUMS, INC.	-16.68%	3.91B
KOSÉ CORPORATION	-7.04%	3.69B

Cosmetics & Perfumes